-
Asymchem Laboratories Enters European Market with Pfizer’s UK API Plant and R&D Lab Purchase
•
Asymchem Laboratories (Tianjin) Co., Ltd (SHE: 002821), a leading China-based Contract Development and Manufacturing Organization (CDMO), has announced the acquisition of a state-of-the-art Active Pharmaceutical Ingredient (API) pilot plant and R&D laboratory in Sandwich, UK. These facilities, previously under the ownership of US pharmaceutical giant Pfizer, mark Asymchem’s inaugural foray…
-
CanSino Biologics Partners with Asymchem Laboratories to Innovate Biopharmaceutical Development
•
CanSino Biologics Inc., (HKG: 6185), a leading vaccine specialist based in China, has entered into a strategic partnership with Asymchem Laboratories (Tianjin) Co., Ltd (SHE: 002821), a Contract Development and Manufacturing Organization (CDMO). This collaboration is designed to drive the development of cutting-edge technologies that align with market demands. The…
-
Shanghai Pharmaceuticals Partners with Asymchem for Advanced Drug Development and Production
•
China-based pharmaceutical distribution giant Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607) has entered into a strategic partnership with compatriot firm Asymchem Laboratories (Tianjin) Co., Ltd (SHE: 002821), a leading Contract Development and Manufacturing Organization (CDMO). This collaboration will span synthetic biotechnology, continuous reaction technology, and the development and production of…
